NSRX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

NS

Mkt Cap

$37.1M

Volume

15.03K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic GrowthNasus Pharma Ltd. (NYSE: NSRX) announced the appointment of Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. O'Grady, a pharmaceutical industry veteran with 35 years of experience and former CEO of Teva USA, will lead the company's growth strategy with focus on commercializing NS002, an intranasal epinephrine treatment for anaphylaxis targeting a $2 billion market opportunity. He succeeds Dan Teleman in the leadership transition.GlobeNewswire Inc. · Jul 28, 2026

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingVirtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1x1 management meeting requests through June 19th.GlobeNewswire Inc. · Jun 26, 2026

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business UpdateNasus Pharma reported positive Phase 2 results for NS002, its intranasal epinephrine powder, demonstrating statistically significant improvements in absorption speed compared to EpiPen®. The company plans to initiate a pivotal study in Q4 2026 and is advancing pipeline candidates NS003, NS004, and NS005 toward first-in-human studies in H2 2026. With $4.3 million in cash as of December 31, 2025, plus a $15 million private placement closed in February 2026, the company is well-funded through Q2 2027.GlobeNewswire Inc. · Mar 25, 2026

Nasus Pharma to Participate in Upcoming Investor ConferencesNasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company developing intranasal products, announced that CEO Dan Teleman will present at three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25), BIO Investment & Growth Summit (Mar 2), and Citizens Life Sciences Conference (Mar 3). The company is focused on developing NS002, an intranasal powder Epinephrine product as a needle-free alternative to autoinjectors for anaphylaxis treatment.GlobeNewswire Inc. · Feb 20, 2026

Nasus Pharma Announces Closing of $15.0 Million Private PlacementNasus Pharma Ltd. (NYSE: NSRX) announced the closing of a private placement raising approximately $15.0 million gross proceeds through the sale of 2,695,425 ordinary shares and accompanying warrants at $5.565 per share. The company plans to use the proceeds to advance its NS002 intranasal epinephrine powder product candidate toward a pivotal study and NDA submission, while expanding its pipeline of intranasal powder-based programs.GlobeNewswire Inc. · Feb 13, 2026

Nasus Pharma Announces Pricing of $15.0 Million Private PlacementNasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company, announced a private placement of 2.7 million ordinary shares and warrants for approximately $15 million in gross proceeds. The funds will be used to advance pivotal clinical development of NS002, an intranasal epinephrine product for anaphylaxis treatment, and to initiate first-in-human studies for other pipeline products.GlobeNewswire Inc. · Feb 11, 2026

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderNasus Pharma reported positive interim Phase 2 results for NS002, its intranasal epinephrine powder for anaphylaxis treatment. The drug demonstrated faster absorption and higher peak epinephrine levels compared to EpiPen, with 91% of participants reaching therapeutic levels at 5 minutes versus 67% with EpiPen. NS002 was well-tolerated with no serious adverse events. Full Phase 2 results are expected by Q1 2026, with pivotal study initiation planned for Q4 2026.GlobeNewswire Inc. · Jan 20, 2026

Nasus Pharma Announces Closing of Initial Public OfferingNasus Pharma completed its initial public offering, raising $10 million by selling 1,250,000 ordinary shares at $8.00 per share. The company plans to use proceeds to develop its intranasal Epinephrine program and for general corporate purposes.Benzinga · Aug 14, 2025

NS

NSRXNasus Pharma Ltd.

NSRX

Pay with—

Available Balance0.00

Your PositionYou don't own any NSRX yet.

Related Tickers

Earnings